FDA Approves Elecsys IL-6 Test for Emergency Use in COVID-19
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Drugmaker Roche has received emergency use authorization from the U.S. Food and Drug Administration for its Elecsys IL-6 test to help identify severe inflammatory response in patients with confirmed COVID-19, it said on June 4.

• Roche noted that the test can support physicians, in combination with other examinations and vital signs, to decide early on if a patient with confirmed COVID-19 disease requires mechanical ventilation.

• This test measures levels of the biomarker interleukin 6 or IL-6, an early indicator for acute inflammation to aid in the management of critically ill patients.

• Hospitals and reference laboratories can run the Elecsys IL-6 test on Roche's Cobas e-analyzers which are widely available around the world.

• These fully-automated systems can provide test results in approximately 18 minutes, with a test throughput of up to 300 tests/hour, depending on the analyzer.

• The Elecsys IL-6 test would identify patients who could be eligible for Actemra, whose sales rose about 30% in the first quarter due largely to the new coronavirus.

Source: https://www.nasdaq.com/articles/roches-elecsys-il-6-test-gets-fda-approval-to-use-in-covid-19-treatment-2020-06-04
Dr. M●●y H●●●y and 4 others like this4 shares
Like
Comment
Share